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ToassesswhetheranticolonizationfactorantigenI(CFA/I)ﬁmbriaeantibodies(Abs)fromenterotoxigenicEscherichiacoli(ETEC)
can protect against various routes of challenge, BALB/c mice were immunized with a live attenuated Salmonella vaccine vector
expressing CFA/I ﬁmbriae. Vaccinated mice elicited elevated systemic IgG and mucosal IgA Abs, unlike mice immunized with the
empty Salmonella vector. Mice were challenged with wild-type ETEC by the oral, intranasal (i.n.), and intraperitoneal (i.p.) routes.
Na¨ ıve mice did not succumb to oral challenge, but did to i.n. challenge, as did immunized mice; however, vaccinated mice were
protected against i.p. ETEC challenge. Two intramuscular (i.m.) immunizations with CFA/I ﬁmbriae without adjuvant conferred
100% protection against i.p. ETEC challenge, while a single 30µg dose conferred 88% protection. Bactericidal assays showed that
ETEC is highly sensitive to anti-CFA/I sera. These results suggest that parenteral immunization with puriﬁed CFA/I ﬁmbriae can
induce protective Abs and may represent an alternative method to elicit protective Abs for passive immunity to ETEC.
1.Introduction
Travelers’ diarrhea still poses risk to inhabitants of endemic
areas [1]. Traveling to such areas results in approximately
40% of travelers experiencing at least one episode of diarrhea
[2], which accounts for 160 million new cases annually [3].
Among the causative agents, enterotoxigenic Escherichia coli
(ETEC)isresponsiblefor ∼76%ofthesecases[4].ETECalso
aﬄicts young children, resulting in the deaths of 300,000–
500,000 children aged <5y e a r s[ 5, 6]. In the United States,
ETEC is considered an emerging cause of foodborne disease
[7]. ETEC is also a diarrheal disease in livestock, especially in
piglets, and represents a signiﬁcant economic burden [8, 9].
Thus, an eﬀective vaccine against ETEC is desirable given
thattherearecurrentlynolicensedvaccinesforhumanETEC
[10].
TheessentialdeterminantsofETECvirulencearedirectly
linkedtotheproductionofﬁmbrialoraﬁmbrialcolonization
factor antigens (CFAs) and heat-stable and/or heat-labile
toxins [8, 11, 12]. Previous studies have shown that CFA/I
ﬁmbriae are expressed on the cell surface of ETEC, facili-
tating its attachment to epithelial cells of the human small
intestine, thus serving as a virulence factor [13]. Challenge
studies in humans suggest that CFA/I ﬁmbriae are protective
antigens (Ags) [13–15]. Previous results from our laboratory
have shown that a single dose of S. typhimurium-CFA/I
vaccine is suﬃcient to elicit elevated secretory immunoglob-
ulin A (SIgA) and systemic IgG antibody (Ab) responses to
CFA/I ﬁmbriae due to the induction of a dominant Th2-type
response [16, 17].
ETEC is host speciﬁc [18], making the testing of ETEC
vaccines diﬃcult. Likewise, eﬀective vaccines for livestock
are lacking, which is in part attributed to host diversity:
K88+ ETEC mostly infects swine [9, 19, 20], and K99+
mostly infects calves and lambs [21–23]. ETEC isolated
from humans harbors CFAs and is the causative agent for
human diarrhea disease [24–26]. Although suitable animal
models for studying human ETEC are not readily available,
previous studies have shown that neutralizing Abs induced
to ETEC in mice can provide possible insight to vaccine2 Journal of Biomedicine and Biotechnology
eﬃcacies [27, 28]. To circumvent host speciﬁcity, others
havesoughtdiﬀerentroutesofinfection,includingintranasal
(i.n.), intraperitoneal (i.p.), and oral routes, to determine
protection with experimental vaccines [27, 29–31]. Rabbits
have also been used to assess protection, using the RITARD
model [32, 33], and one such study shows the ability of
mouseIgGmAbsagainstCFAstoconferprotection[32].Ina
similarvein,chickenyolkIgYAbsareabletopassivelyprotect
using the RITARD model [33]. Thus, while local production
ofprotectiveAbswouldbeidealforprotectionagainstETEC,
immuneAbsderivedfrommilk[34],yolk[33],ormAbs[32]
are possible alternatives to locally produced SIgA.
In this study, we questioned whether protective Abs
induced to ETEC would be protective against diﬀerent
routes of challenge. We elected to use two formulas of the
CFA/I subunit vaccines in this study: one is carried by the
Salmonella vaccine vector H683, and the other formulation
uses puriﬁed CFA/I ﬁmbriae protein. A S. typhimurium-
derived vaccine strain was used in this study because,
although S. typhimurium and S. Typhi are both human
pathogens, S. Typhi does not normally infect mice [35].
Other live vectors for carrying CFA/I ﬁmbriae such as E. coli
were excluded since our previous work had shown that the
E. coli-based vaccine is not suﬃciently immunogenic [36].
In contrast, heterologous gene expression by Salmonella had
previously been shown to be highly immunogenic [16, 17],
and this mucosal vaccine has the advantage of being needle-
free and does not require cold-chain preservation. Moreover,
eﬃcacy by the puriﬁed CFA/I ﬁmbriae was conducted.
I.n. ETEC challenge was proposed as an alternative
means to infect mice [27]. However, mice orally immu-
nized with Salmonella-CFA/I proved ineﬀective against nasal
challenge but were protected against i.p. challenge, showing
that the induced immune IgG Abs are protective against
ETEC. Moreover, i.m. immunization with recombinant
CFA/I ﬁmbriae with or without adjuvant was also found
to be neutralizing, suggesting that i.p. infection provides an
alternative means to assess protective Abs elicited by ﬁmbrial
vaccines.
2.MaterialsandMethods
2.1. Bacterial Strains, Plasmids, and Media. The bacterial
strains, plasmids, and their relevant characteristics are
provided in Table 1. Strains containing plasmids were grown
at37◦CinLysogenybroth(LB;10goftryptone,10gofNaCl,
and 5g of yeast extract/L). Diaminopimelic acid (DAPA)
(50µg/mL) was used for E. coli H681 or S. typhimurium
H683 culture, unless a plasmid containing asd gene was
introduced. Wild-type (wt) ETEC strain H10407 is a human
isolate commonly used in challenge experiments [37].
H10407 was selected due to its prototypical feature of ETEC,
that is, it reproducibly elicits diarrhea in human volunteer
studies [39]. Additionally, CFA/I ﬁmbriae used in this study
were originally cloned from this strain [36]. The wt ETEC
B41 is a bovine pathogen [38]. To investigate whether the
anti-CFA/IseraareabletoneutralizetheheterologousETEC,
strain B41 was selected since it produces K99 ﬁmbriae.
Bacteria were cultured in LB and stored at −80◦Ci nL Bp l u s
20% glycerol.
Previous work has shown that the cfa/I operon is
expressed constitutively in plasmid pJGX15C-asd [36], and
its regulation is under the control of a tetracycline promoter
(PtetA). To enhance cfa/I expression, the macrophage-
inducible promoter from S. typhimurium H683 phoP gene
(PphoP) was selected [40]t oe n a b l ecfa/I expression. The
PphoP from plasmid pV4 was digested with NheIa n d
SacI restriction enzymes, as previously done, to enhance
plague F1- and V-Ags [41], and this DNA segment was
subsequently puriﬁed from agarose gel and inserted to
pJGX15C-asd between NheIa n dSacI sites, replacing PtetA.
This new plasmid is referred to as pC1 (Table 1). Expression
of CFA/I ﬁmbriae was conﬁrmed by Western blot analysis, as
previously described [41].
2.2. CFA/I Fimbrial Protein Isolation and Puriﬁcation. CFA/I
ﬁmbrial protein isolation and puriﬁcation from E. coli H695
were performed, as previously described [16, 42]. Since
C F A / Iﬁ m b r i a ea r ep r o d u c e di nE. coli, contaminating LPS
was removed using Detoxi-Gel Endotoxin Removal Gel
(Pierce, Rockford, ILL). CFA/I ﬁmbriae were allowed to
incubate on the resin for 3-4 hours (hrs) to increase contact
time with the polymyxin B and applied to the resin multiple
times (typically 2–4 times) until the endotoxin levels were
below 6.4ng/mL in sterile phosphate buﬀered saline (sPBS).
The limulus amebocyte lysate (LAL) test (Associates of Cape
Cod, Inc., East Falmouth, Mass) was used according to
manufacturer directions to verify endotoxin levels.
2.3. Immunization and Challenge of Mice. Female BALB/c
mice at 7 to 9wk of age were obtained from Frederick Cancer
Research Facility (National Cancer Institute, Frederick, Md)
and used throughout the study, as previously described
[16]. All mice were maintained in laminar ﬂow racks
under conditions of 12hr of light and 12hr of darkness
a n dp r o v i d e dw i t hf o o da n dw a t e rad libitum. All animal
experiments, including immunization and challenge, were
performed at the Montana State University Animal Resource
Center. All animal care and procedures were in accordance
with institutional policies for animal health and well-being.
S. typhimurium H683-pC1, control S. typhimurium
H647, and wt ETEC strains H10407 and B41 were grown
overnight in LB at 37◦C. H683-pC1 and H647 cells
were pelleted, washed twice in sPBS, and diluted to 5 ×
109 cells/200µL in sPBS. The actual viable inoculum, colony-
forming unit (CFU), was conﬁrmed by serial dilution test
on LB agar plate. Mice (5 per group) were orally immunized
twice with 200µL of the bacterial suspension on days 0 and
28. The experiment was repeated twice.
For oral challenges, wt ETEC H10407 was diluted in
sPBS in which 200µL of bacterial suspension contained 5 ×
109 or 5 × 108 CFUs of bacteria and was used to orally
gavage mice previously treated with a 100µL 50% saturated
sodium bicarbonate solution 30min prior to challenge, as
previously described [17]. For i.n. challenges, mice were
lightly anesthetized by inhalational isoﬂurane (HalocarbonJournal of Biomedicine and Biotechnology 3
Table 1: Bacterial strains, plasmids, and their characteristics.
Bacterial strains Characteristics Sources or references
E. coli H681 asd− [31]
E. coli H695 cfa/I+ [16]
enterotoxigenic E. coli H10407 wt, serotype 078:K80:H11 [37]
enterotoxigenic E. coli B41 wt, serotype O101:K− [38]
S. typhimurium H683 asd−aroA− [31]
S. typhimurium H647 asd+ [31]
Plasmids
pJGX15C-asd cfa/I+ [36]
pC1 derived from pJGX15C-asd This study
Products Corp, River Edge, NJ) and subsequently infected
with wt ETEC H10407 diluted in sPBS containing 5 × 109
or 5 × 108 CFUs of bacteria in 50µL applied dropwise to
the nares using 25µL/nostril, as previously described [27].
For i.p. challenges, wt ETEC H10407 diluted in 200µL
sPBS containing 5 × 107 CFUs was then subsequently
injected. Challenge was performed at 7-wk postprimary
immunization, and the challenge doses were conﬁrmed by
plating H10407 on LB agar after serial dilutions of the
inoculum.
For the CFA/I ﬁmbriae immunization studies, mice were
immunized with puriﬁed, low-endotoxin CFA/I ﬁmbriae in
sPBS (1.2–3.0µg/µL) by intramuscular (i.m.) injection. Two
doses of 60µg, 100µg, or 150µg CFA/I ﬁmbriae at 2-wk
intervals were injected into BALB/c mice tibialis anterior
muscles.Asanegativecontrol,additionalmiceweresimilarly
immunized with sPBS. The volume used for injection was
25µL per leg. At the indicated time intervals, serum and fecal
samples were collected to assess serum IgG and IgG subclass
and fecal IgA endpoint titers. In each experiment, 3-4 mice
per group were used, and the experiment was done twice for
a total of 7 mice per group.
For some experiments, mice were i.m. immunized with a
single10or30µgdoseofpuriﬁed,low-endotoxinCFA/Iﬁm-
briae with or without the coadministration of the mucosal
adjuvant, cholera toxin (CT) (List Biological Laboratories,
Campbell, Calif). At 0, 2, and 3wks after immunization,
serum IgG and mucosal IgA anti-CFA/I endpoint titers were
measuredby ELISA. Challenge with wtETEC was performed
at 4-wk postprimary immunization. In each experiment, 4
mice per group were used, and the experiment was done
twice for a total of 8 mice per group.
For mouse colonization studies, mice (5 per group) were
immunized with 10µg detoxed CFA/I ﬁmbriae plus 2.5µg
CT, or given PBS only. At 3wks after immunization, mice
were i.p. challenged with 5 × 107 CFUs of wt ETEC H10407.
At 4, 8, and 16hr after challenge, spleen, liver, kidneys, and
lungs from individual mice were mechanically homogenized
in sterile Milli-Q water. Samples were serially diluted on LB
agarforovernightincubationat37◦C,andthebacterialCFUs
were enumerated.
2.4. Endpoint Ab Titer Determinations. To determine the
inducedserumandmucosalAbstoCFA/Iﬁmbriae,endpoint
titers were measured, as previously described by CFA/I
ﬁmbriae-speciﬁc ELISA [16, 17]. Speciﬁc reactivities to
CFA/I ﬁmbriae were determined using horseradish peroxi-
dase conjugates of detecting Abs: goat antimouse IgG, IgA,
IgG1, IgG2a, IgG2b, or IgG3 Abs (Southern Biotechnology
Associates, Birmingham, Ala) in combination with sub-
strate, 2,2 -azinobis (3-ethylbenzthiazoline-6-sulfonic acid)
diammonium (Moss Inc., Pasadena, CA). Absorbances were
read at 415nm on an ELx808 microplate reader (Bio-Tek
Instruments, Winooski, Vt). Endpoint titers were expressed
as the reciprocal of the last sample dilution giving an
absorbance of 0.1 optical density (OD) unit at 415nm above
the OD415 of negative controls after 1-hr incubation at room
temperature.
2.5. Bactericidal Test. Sera collected from the CFA/I
ﬁmbriae-immunized mice and the sPBS-dosed mice were
diluted with sPBS [43] by 2-, 4-, and 8-fold. An equal
volume of wt ETEC H10407 and B41 cells harvested from
logarithmic phase with a density of 500–1,000CFUs/µL
was added to the nondiluted and diluted sera. Thus, the
serum was ﬁnally diluted to 2-, 4-, 8-, and 16-fold in the
bacteriaandserummixtures.Samplesweremixedevenlyand
incubated at 37◦C for 0, 20, 40, and 60min. Subsequently,
samples were removed after thorough mixing and colony
countsmadeateachtimepoint,aspreviouslydescribed[41].
This experiment was done three times.
2.6. Statistical Analysis. The Student’s t-test was used to
evaluate the diﬀerences between experimental parameters
in each experiment, and the P values < 0.05 are indicated.
The Kaplan-Meier method (GraphPad Prism, GraphPad
Software, Inc., La Jolla, CA) was applied to obtain the mouse
survival fractions following infection with a lethal dose of wt
ETEC strain H10407. Using the Mantel-Haenszel log rank
test,theP valuesforstatisticaldiﬀerencesbetweenvaccinated
and na¨ ıve mice were discerned at the 95% conﬁdence
interval.
3. Results
3.1. Oral Immunization with S. typhimurium H683-pC1
Vaccine Stimulates Elevated Serum and Mucosal Anti-CFA/I
Fimbriae Abs. To evaluate the ability of S. typhimurium4 Journal of Biomedicine and Biotechnology
H683-pC1 to elicit anti-CFA/I titers, two groups of BALB/c
mice were orally immunized with 5 × 109 CFUs of H683-
pC1 and H647, respectively. Mice were boosted 4wks later
with the same dose, and anti-CFA/I ﬁmbriae endpoint titers
were determined for both serum IgG and copro-IgA Abs.
At wk 6 postprimary immunization, serum IgG anti-CFA/I
ﬁmbriae titers were 216.8, and copro-IgA anti-CFA/I titers
were 28.8 (Figure 3(a)), suggesting that H683-pC1 was highly
immunogenic.Minimaltonoanti-CFA/Iﬁmbriaetiterswere
observed in the empty Salmonella vector H647-immunized
mice, similar to that previously described [16, 36]. At wk
6, serum IgG subclass responses to CFA/I ﬁmbriae were
also measured. The IgG1 titers were similar to IgG2a, but
signiﬁcantly greater than IgG2b (P<0.05) and IgG3 (P<
0.001) Ab titers, and the IgG2a titers were signiﬁcantly
greater than IgG3 Ab titers (P<0.01) (Figure 3(b)). These
results indicate that IgG1, IgG2a, and IgG2b subclasses
dominated the serum anti-CFA/I IgG response, implicating
that a mixed Th cell response was induced by H683-pC1.
3.2. Oral Immunization with H683-pC1 Protects against I.P.
Challenge with wt ETEC. To determine whether routes
of challenge inﬂuence susceptibility to ETEC infection,
H683-pC1- and H647-immunized mice (Figure 3(a))w e r e
challenged via oral (Figure 3(c)), i.n. (Figure 3(d)), or i.p.
(Figure 3(e)) routes with wt ETEC strain H10407. All mice
survived either oral challenge dose (5×108 CFUs and 5×109
CFUs) (Figure 3(c)). All mice survived nasal challenge with
the low dose of 5 × 108 CFUs (Figure 3(d)), but only 50%
of the mice from H683-pC1- and H647-immunized groups
survived the high dose of 5×109 CFUs. Only one dose of 5×
107 CFUs was tested for i.p. challenge, and 80% of the H683-
pC1-immunized mice were protected (P<0.05), unlike
the H647-immunized mice that succumbed to challenge
(Figure 3(e)). These results show mice are not susceptible to
the oral challenge route by the human ETEC strain H10407.
Moreover, nasal challenge also proved insuﬃcient against
the low dose (5 × 108 CFUs) challenge, while a high-dose
(5 × 109 CFUs) proved to be lethal since 50% of H683-
pC1- and H647-vaccinated mice succumbed to infection.
However, H683-pC1-vaccinated mice were protected against
i.p. challenge, and control mice (H647-vaccinated) were
sensitive to the i.p. route of challenge by human ETEC.
3.3. Puriﬁed CFA/I Fimbriae Eﬀectively Stimulate Elevated
Ab Reponses following I.M. Immunization. Previous studies
have shown that anti-CFA/I ﬁmbriae Abs are protective
against ETEC infection [14, 15, 34]. While Abs induced
subsequent to oral immunization with the Salmonella-based
vaccine protected mice from ETEC challenge (Figure 3(e)),
we questioned whether immunizing mice with the CFA/I
ﬁmbriae alone would be suﬃcient to confer protection.
BALB/c mice were i.m. immunized with sPBS-buﬀered
detoxed CFA/I ﬁmbriae at doses of 60µg, 100µg, or 150µg,
with sPBS as a control. They were subsequently boosted
2wks later with the same doses. The CFA/I ﬁmbriae induced
robust immune responses (Figures 1(a)–1(c)), and sPBS-
dosed mice showed no anti-CFA/I Ab titers (Figure 1(d)).
Regardless of immunization dose, copro-IgA titers amongst
the three immunization groups did not diﬀer signiﬁcantly
a n da t t a i n e da sm u c ha s2 7.1. Serum IgG titers at wk 3 were
greatly elevated between 216and 217.4. Although no statistical
diﬀerences were obtained in IgG titers between the groups
immunizedwith60and100µgofCFA/Iﬁmbriae,thesetiters
were signiﬁcantly greater than the group immunized with
150µgd o s e( Figure 1(a) versus 1(c), P<0.05; Figure 1(b)
versus Figure 1(c), P<0.001). These results suggest that
increasing the dose of CFA/I ﬁmbriae does not necessarily
enhance the humoral immune response. Collectively, these
results indicate that as little as 60µgC F A / Iﬁ m b r i a ei s
suﬃcient for eliciting elevated serum IgG and mucosal IgA
anti-CFA/I titers.
Sera from the 60µg, 100µg and 150µgC F A / Iﬁ m b r i a e -
immunized mice at 3-wk postprimary immunization were
further analyzed for IgG subclass responses. For all tested
doses, the IgG1 titers were signiﬁcantly greater than IgG2a,
IgG2b, and IgG3 titers, while no statistical diﬀerences were
found among IgG2a, IgG2b, and IgG3 titers (Figures 1(a)–
1(c)). This result shows that the CFA/I ﬁmbrial immu-
nization favors an IgG1 Ab response that diﬀers from
live vaccine H683-pC1 immunization, which sustains a
balanced immune response between IgG1 and IgG2a Abs
(Figure 3(b)).
3.4.ImmunizationwithCFA/IFimbriaeProtectsMicefromWt
ETEC Challenge. To evaluate whether the CFA/I ﬁmbriae-
immunized mice would protect against i.p. ETEC challenge,
the above-immunized BALB/c mice (Figure 1)w e r ei . p .
challenged with 5 × 107 CFUs of wt ETEC H10407. The
mice immunized with 60µg CFA/I ﬁmbriae showed 100%
eﬃcacy (7/7), while 14.3% of the sPBS-dosed mice survived
(1/7) (P<0.05) (Figure 1(e)). Thus, the detoxed subunit
vaccine, CFA/I ﬁmbriae, stimulated protective immunity.
However, mice were immunized with 100µg and 150µg
CFA/I ﬁmbriae, and the survival rates diminished to 71.4%
(5/7) and 42.9% (3/7), respectively (Figure 1(e)). This out-
comeshowsthatbyincreasingtheCFA/Iimmunizationdose,
the protective eﬃcacy diminishes. Given these ﬁndings, it
may be possible to lower the dose of CFA/I ﬁmbriae while
maintaining protective eﬃcacy.
3.5. Determination of the Minimal Dose of CFA/I Fimbriae
to Elicit Protective Immunity. To determine the minimal
dose that can achieve protection against i.p. ETEC challenge
in BALB/c mice, two doses of detoxed CFA/I ﬁmbriae
were tested: 30 and 10µgp e rm o u s e .A sn a ¨ ıve control, an
additional group of mice was given sPBS. In addition, three
more groups were given the same doses, but coadministered
with 2.5µg CT. CT is a powerful adjuvant that induces
immune responses to coadministered Ags [44]. CT was
selectedasanadjuvantbecauseofitsTh2cellbias[45],which
favors heightened humoral immune responses particularly
beneﬁcial for clearing extracellular pathogens [46], such as
ETEC [47]. After i.m. immunization, individual copro-IgA
and serum IgG endpoint titers were determined at 0, 2,
and 3wks after immunization (Figures 2(a)–2(c)). ElevatedJournal of Biomedicine and Biotechnology 5
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Figure 1: Evaluation of the protective immunity of the detoxed CFA/I ﬁmbriae. (a)–(d) Endpoint Ab titers were induced to detoxed CFA/I
ﬁmbriae. BALB/c mice (7/group) were i.m. immunized with (a) 60, (b) 100, (c) 150, or (d) 0µg CFA/I ﬁmbriae on days 0 and 14. Serum IgG
andmucosalIgAanti-CFA/IﬁmbriaeendpointAbtitersweremeasuredat0,2,and3-wkpostprimaryimmunization.IgGsubclassresponses
were determined at wk 3, and ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001 versus IgG1 titers. (e) Assessment of the protective eﬃcacy against
i.p. ETEC challenge was determined. CFA/I ﬁmbriae-immunized mice (a)–(c) and sPBS-dosed mice (d) were i.p. challenged with 5 × 107
CFUs of wt ETEC H10407 at 4-wk postprimary immunization. Mouse survival rates were observed for 14 days. The survival rates of 60µg,
100µg, and 150µg CFA/I ﬁmbriae-immunized mice were 100% (7/7), 71.4% (5/7), and 42.9% (3/7), respectively, versus 14.3% (1/7) for
sPBS-dosed mice. Survival fractions obtained from vaccinated mice were compared to sPBS-dosed mice, and signiﬁcance was determined:
∗P<0.05.6 Journal of Biomedicine and Biotechnology
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Figure 2: Evaluation of protective immunity induced by a low dose of CFA/I ﬁmbriae. BALB/c mice (6–8/group) were i.m. immunized with
(a) 30, (b) 10, and (c) 0µg detoxed CFA/I ﬁmbriae with or without CT on day 0. (a, b) Elevated serum IgG and mucosal IgA anti-CFA/I
Ab ﬁmbriae responses were induced by 2wks after immunization (c), but not by control mice. Depicted is the mean ± SD as ∗∗P<0.01
and ∗∗∗P<0.001 versus 10µg CFA/I ﬁmbriae-immunized mice. (d) Assessment of the protective eﬃcacy by the low-dose CFA/I ﬁmbriae-
immunizedmice.TheCFA/Iﬁmbriae-immunizedandsPBS-dosedmice(a)–(c)werei.p.challengedwith5×107 CFUsofwtETECH10407at
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compared to sPBS-dosed mice and were determined, ∗P<0.05 and †P<0.05, respectively.
serum IgG anti-CFA/I titers were obtained for both 10 and
30µg CFA/I ﬁmbriae-dosed mice (Figures 2(a) and 2(b)),
while the sPBS-dosed mice displayed only background titers
(Figure 2(c)). Generally, the immune responses elicited by
the30µgCFA/Iﬁmbriaeweresigniﬁcantlygreaterthan10µg
CFA/I ﬁmbriae for mucosal IgA; without CT, the titers of
30µg were compared with 10µgC F A / Iﬁ m b r i a e :2 2.3 versus
20.0 at wk 3 (P<0.05); with CT, 23.8 versus 20.4 at wk
2( P<0.01) and 22.8 versus 20.0 at wk 3 (P<0.01);
and IgG, without CT, the titers of 30µgw e r ec o m p a r e dt o
10µgC F A / Iﬁ m b r i a e :2 15.4 versus 212.5 at wk 3 (P<0.05);
with CT, there was no signiﬁcant diﬀerence. These resultsJournal of Biomedicine and Biotechnology 7
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Figure 3: Salmonella vaccine H683-pC1 stimulates elevated anti-CFA/I ﬁmbriae Ab titers and protects against i.p. ETEC challenge. (a)
BALB/c mice (5/group) were orally immunized twice on days 0 and 28 with 5 × 109 CFUs of S. typhimurium H683-pC1 and H647,
respectively. Elevated serum IgG and mucosal IgA anti-CFA/I ﬁmbriae Ab responses were induced. Depicted are the mean ± SEM from two
independent experiments. (b) At wk 6, serum IgG subclass analysis was performed, and statistical diﬀerences in the endpoint Ab titers were
determined. ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001 versus IgG1; ¶¶P<0.01 versus IgG2a. (c)–(e) Comparison of diﬀerent routes of challenges
with wt ETEC H10407 among CFA/I ﬁmbriae-immunized BALB/c mice. At 6-wk postprimary immunization, mice were challenged with wt
ETEC H10407 (c) orally with 5×108 or 5×109 CFUs, (d) i.n. with 5×108 or 5×109 CFUs, or (e) i.p. with 5×107 CFUs. Mice survival was
monitored for two wks. Results are from two independent experiments; survival fractions obtained from vaccinated mice were compared to
H647-immunized mice, and signiﬁcance was determined; ∗P<0.05.8 Journal of Biomedicine and Biotechnology
456789
CFA
PBS
CFA
PBS
CFA
PBS
CFA
PBS
Bacterial CFU/g of tissue (log10)
Time
4hr
Lung
Kidney
Liver
Spleen
(a)
Bacterial CFU/g of tissue (log10)
45678
Time
8hr
(b)
Bacterial CFU/g of tissue (log10)
6789 1 0
∗
∗∗
Time
16hr
∗
(c)
Figure 4: ETEC colonization in CFA/I ﬁmbriae-immunized mice. Determination of ETEC colonization in mouse spleen, liver, lungs, and
kidneys subsequent to ETEC challenge at (a) 4, (b) 8, and (c) 16hr by CFA/I ﬁmbriae-immunized (10µg CFA/I ﬁmbriae + 2.5µgC T )o r
PBS-dosed mice. Depicted is the mean ± SD for diﬀerences in bacterial CFUs between CFA/I-dosed and sPBS-dosed mice; ∗P<0.05 and
∗∗P<0.01.
indicate that unlike the 30µg CFA/I ﬁmbrial dose, 10µg
CFA/I ﬁmbriae alone is insuﬃc i e n tt oc o n f e rp r o t e c t i o n
unless coadministered with CT adjuvant.
From the Ab titer measurements, the impact of CT
adjuvant was not apparent when combined with the 30µg
CFA/I ﬁmbrial dose, since with or without CT, no signiﬁcant
diﬀerences were observed in serum IgG and mucosal IgA Ab
titers (Figure 2(a)). However, the impact of CT adjuvant was
evident in the CFA/I ﬁmbrial dose of 10µg since signiﬁcantly
elevated IgG titers were achieved upon CT coadministration:
213.9 versus 211.6 at wk 2 (P<0.01) and 215.9 versus 212.5 at
wk 3 (P<0.001) (Figure 2(b)). This ﬁnding suggests that
10µg of CFA/I ﬁmbriae requires adjuvant to induce elevated
Ab titers.
To test whether the single low dose of CFA/I ﬁmbriae
was suﬃcient to confer protection, the above-immunized
BALB/c mice (Figures 2(a)–2(c)) were challenged i.p. with
5 × 107 CFUs of wt ETEC H10407. Of the mice immunized
with 10 and 30µg CFA/I ﬁmbriae coadministered with CT,
the survival rates were 100% (8/8 and 8/8) for both groups,
but the survival rates for mice immunized with 30 and
10µg CFA/I ﬁmbriae without CT were 87.5% (7/8) and
62.5% (5/8), respectively (Figure 2(d)). The survival rates
for mice given CT or sPBS were only 25% (2/8) and 0%
(0/6), respectively (Figure 2(d)). Importantly, the survival
ratesforthetwogroupsimmunizedwitheitherdoseofCFA/I
ﬁmbriae in combination with CT were signiﬁcantly greater
than that of the sPBS-dosed group (P<0.05) (Figure 2(d)).
This shows that a single low dose of CFA/I ﬁmbriae with
adjuvant can achieve full protection. In the absence of
adjuvant, immunization with 30µg CFA/I ﬁmbriae achieved
ap r o t e c t i v ee ﬀect very close to full protection (Figure 2(d));
nonetheless, 60µg CFA/I ﬁmbriae alone could achieve 100%
protection (Figure 1(e)).
3.6. ETEC Colonization following CFA/I Fimbrial Immu-
nization. Since recombinant CFA/I ﬁmbriae conferred full
protection to mice, we questioned how much ETEC col-
onized the various tissues in the protected mice. Groups
of BALB/c mice were i.m. immunized with 10µgd e t o x e d
CFA/I ﬁmbriae plus 2.5µg CT or with PBS alone. At 3wks
after immunization, mice were i.p. challenged with 5 × 107
CFUs of wt ETEC H10407. Since na¨ ıve mice could succumb
to ETEC challenge by 24hr after challenge (Figures 3(e)
and 3(d)), bacterial CFU levels were measured at 4, 8, and
16hr after challenge for spleen, liver, kidneys, and lungs.
The results showed no signiﬁcant diﬀerences in colonization
between CFA/I- and sPBS-immunized mice at 4 and 8hr
after challenge in spleen, liver, kidneys, and lungs (Figures
4(a)and4(b)).However,at16hrafterchallenge,thebacterial
CFUs from CFA/I-immunized mice were signiﬁcantly less
than sPBS-dosed mice in spleen, liver, and kidneys by 27.9-
fold (P<0.05), 4.3-fold (P<0.05), and 11.1-fold (P<
0.01), respectively (Figure 4(c)). Although the lungs showed
no signiﬁcant diﬀerences, the bacterial CFUs appeared to
be diminished in the CFA/I-immunized mice relative to
sPBS controls. These results suggest the ETEC replication
in the immunized mice is reduced following CFA/I ﬁmbrial
immunization.
3.7. Evaluation of the Bactericidal Activity of the CFA/I
Fimbriae-Immunized Mouse Sera. Since the serum IgG titers
correlate to protective immunity, we questioned whetherJournal of Biomedicine and Biotechnology 9
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Figure 5: The sera from the CFA/I-immunized mice are eﬀective in killing wt CFA/I+ ETEC H10407 but not K99+ ETEC B41. The sera of
the 60µg CFA/I-immunized mice were compared to those from sPBS-dosed mice (Figure 1) for bactericidal activity serially diluted (a, e) 2-,
(b, f) 4-, (c, g) 8-, and (d, h) 16-fold. Depicted are the percentages of the survival bacterial CFU relevant to the initial bacterial CFU before
supplement of sera (time = 0min). At 20, 40, and 60min after incubation, the bacterial survival rates were statistically calculated between
anti-CFA/I sera and the -sPBS sera via Student’s t-test: ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001. Values are the mean ± SEM (n = 3).
protection conferred by the CFA/I ﬁmbriae was due to
the bactericidal eﬀects from the sera. The sera from the
60µg CFA/I ﬁmbriae-immunized mice were assessed for
the bactericidal activity with the sPBS-dosed mouse sera
as the control (Figure 1). The results showed that sera
from the sPBS-dosed mice displayed no bactericidal eﬀect
to H10407 (Figures 5(a)–5(d)). However, 2-fold dilution
of the anti-CFA/I sera killed all H10407 ETEC within
20min (Figure 5(a)); at 4- and 8-fold dilution, they were
all killed within 40min (Figures 5(b) and 5(c)); and at
16-fold dilution, 79.5% of the bacteria was killed within
60min (Figure 5(d)). These results clearly indicate that the
anti-CFA/I sera are highly eﬀective in killing homologous
bacteria, conﬁrming the observation that CFA/I-immunized
mice were protected from wt ETEC challenge.
To determine whether the anti-CFA/I sera were able
to neutralize the heterologous ETEC pathogen B41, a B41
bactericidal assay was performed, similar to the H10407
bactericidal assay. The results showed that the anti-CFA/I
sera were ineﬀective in killing B41 (Figures 5(e)–5(h)). At
2- and 4-fold dilutions, B41 CFUs showed no diﬀerences
between anti-CFA/I sera and control sera treatment at any
time points (Figures 5(e) and 5(f)). For the 8- and 16-
fold dilutions, the anti-CFA/I sera seemed to stimulate
the reproduction of B41 since its CFUs were signiﬁcantly
increased when compared to control sera treatment for 40–
60minafterincubation(Figures5(g)and5(h)).Theseresults
show that anti-CFA/I sera are not eﬀective for neutralizing
K99+ ETEC.
4. Discussion
Although a previous study had shown that human ETEC
H10407 is lethal to BALB/c mice when given nasally at the
dose of 7 × 108 CFUs [27], in our study, nasally admin-
istered H10407 was not lethal to BALB/c mice. Increasing10 Journal of Biomedicine and Biotechnology
the infection dose by one log resulted in only 50% lethality,
and no protective eﬀect was conferred upon oral vaccination
(Figure 3(d)). Similarly, oral challenge was ineﬀective, since
H10407 was not lethal (Figure 3(c)). Alternatively, mice were
highly sensitive to ETEC when challenged i.p. (Figure 3(e)).
It remains unclear why i.n. ETEC infection was ineﬀec-
tive, while i.p. challenge allowed evaluation of protective
Abs to ETEC, especially antiﬁmbrial Abs. As shown, oral
immunization with a Salmonella vaccine expressing CFA/I
ﬁmbriae elicited elevated serum and mucosal Abs capable
of conferring protection against i.p. ETEC challenge. This
result was similar to the previous observation that mice
are sensitive to swine ETEC via i.p., which is able to
distinguish the immunized from the nonimmunized control
[29]. Since Salmonella does disseminate systemically [4], it
readily immunizes systemically, eliciting elevated Ag-speciﬁc
Abs, as evidenced here. Our study shows that parenterally
induced antiﬁmbrial Abs are protective, similar to those
which had been shown in the case of rabbits [32, 33].
Alimitationofﬁmbrialproteinsfororalimmunizationis
itslackofeﬃcacy[48,49]presumablyattributedtoitsdenat-
u r a t i o ni nt h eG It r a c t[ 50]. Aside from problems associated
with live vaccines or the limitations of oral immunization
withkilledETEC[51],onepossiblealternativeforprotection
of newborns is via passive immunity, which has been proven
eﬀective [31, 33, 52]. To this end, studies were conducted
using low-endotoxin CFA/I ﬁmbriae to assess whether i.m.
immunization would be eﬀective to stimulate antiﬁmbrial
Abs. Interestingly, i.m. immunization with the recombinant
CFA/I ﬁmbriae was found to stimulate elevated serum IgG
and mucosal IgA Abs in the absence of adjuvant. In fact, as
little as 60µg, given twice, was suﬃcient to confer complete
protection against i.p. ETEC challenge. Moreover, as little
as a single dose with 30µgw a ss u ﬃcient to confer 88%
protection. Coadministration of CT adjuvant was able to
provide 100% protection achieved with a single dose of
10µgC F A / I .L e s se ﬃcacious, the oral Salmonella vaccine
elicited 80% protection, implicating the possible advantage
of parenteral booster immunizations. Further studies using
sera from CFA/I ﬁmbriae-immunized mice exhibited robust
bactericidal activity against wt ETEC H10407 since after 16-
fold dilution it was still able to kill nearly all bacteria within
1hr. These ﬁndings clearly indicate that CFA/I ﬁmbriae are
eﬀective immunogens for stimulating protective immunity,
suggesting that booster immunizations with puriﬁed ETEC
ﬁmbriae could be given to pregnant mothers to ensure
stimulation of protective Abs. For ETEC vaccines, there may
besomestrain(ﬁmbriae)speciﬁcitysincetheanti-CFA/Isera
did not show any bactericidal activity against K99+ ETEC,
strain B41. Although other ETEC strains may be sensitive to
the enhanced CFA/I bactericidal activity, these results imply
Ag speciﬁcity for optimal impact.
Serum IgG subclass responses revealed that immuniza-
tion with detoxed CFA/I ﬁmbriae favored an IgG1 (Th2-
type) immune response, as opposed to the live Salmonella
vaccine that induced both IgG1 and IgG2a Abs, suggesting
that a mixed Th1 and Th2 phenotype was induced. In the
absence of CFA/I ﬁmbriae, the Salmonella vaccine vector
normally stimulates a Th1 cell response [16]. Although
the protective eﬃcacy of anti-Salmonella infection was not
evaluated, we have previously shown that our Salmonella-
based ETEC vaccines are protective against wt Salmonella
infections [53]. An eﬀective bivalent vaccine for both ETEC
and salmonellosis would assist in control of these two
relevant human diarrheal pathogens.
In summary, this study shows that parenteral immuniza-
tion with puriﬁed CFA/I ﬁmbriae potently induces serum
IgG Abs in the absence of adjuvant. With adjuvant, single-
doseimmunizationwasachievedandproveneﬀectiveagainst
i.p. challenge with ETEC. Since there is not currently a
vaccine for ETEC that can aﬀord sustained and broad-
based protection [51], exploring alternative immunization
regimens, as described here or coupled with transcutaneous
immunization methods [54], may provide some helpful
beneﬁts. Alternatively, additional universal protective Ags
may be necessary, as suggested by others [55].
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